MX2013001269A - Prediccion de cinetica viral de hcv en tratamiento libre de interferon. - Google Patents

Prediccion de cinetica viral de hcv en tratamiento libre de interferon.

Info

Publication number
MX2013001269A
MX2013001269A MX2013001269A MX2013001269A MX2013001269A MX 2013001269 A MX2013001269 A MX 2013001269A MX 2013001269 A MX2013001269 A MX 2013001269A MX 2013001269 A MX2013001269 A MX 2013001269A MX 2013001269 A MX2013001269 A MX 2013001269A
Authority
MX
Mexico
Prior art keywords
interferon
prediction
free treatment
hcv viral
viral kinetics
Prior art date
Application number
MX2013001269A
Other languages
English (en)
Inventor
Tom Chu
Uri Lopatin
Nancy Shulman
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013001269A publication Critical patent/MX2013001269A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención está basada en el descubrimiento de que existen asociaciones entre polimorfismos de un solo nucleótido (SNP) sobre el cromosoma 19 y resultados virológicos en una población diversa de pacientes con virus de hepatitis C (HCV) que recibieron libre de interferón.
MX2013001269A 2010-08-05 2011-08-03 Prediccion de cinetica viral de hcv en tratamiento libre de interferon. MX2013001269A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37090310P 2010-08-05 2010-08-05
PCT/EP2011/063327 WO2012016995A1 (en) 2010-08-05 2011-08-03 Prediction of hcv viral kinetics in interferon-free treatment

Publications (1)

Publication Number Publication Date
MX2013001269A true MX2013001269A (es) 2013-11-27

Family

ID=44503817

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001269A MX2013001269A (es) 2010-08-05 2011-08-03 Prediccion de cinetica viral de hcv en tratamiento libre de interferon.

Country Status (14)

Country Link
US (1) US20120196272A1 (es)
EP (1) EP2601313A1 (es)
JP (1) JP5756175B2 (es)
KR (1) KR101570914B1 (es)
CN (1) CN103052719B (es)
AU (1) AU2011287642B2 (es)
BR (1) BR112013002531A2 (es)
CA (1) CA2802272A1 (es)
MX (1) MX2013001269A (es)
MY (1) MY183794A (es)
NZ (1) NZ604125A (es)
RU (1) RU2590691C2 (es)
SG (1) SG187106A1 (es)
WO (1) WO2012016995A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
UY34402A (es) 2011-10-21 2013-05-31 Abbvie Inc Métodos para el tratamiento de hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) * 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US20130137084A1 (en) * 2011-11-28 2013-05-30 Roche Molecular Systems, Inc. Single Nucleotide Polymorphism on Chromosome 15 That Predicts HCV Treatment Responses
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN108220424A (zh) * 2018-02-05 2018-06-29 广州和康医疗技术有限公司 一种检测il28基因位点的方法及试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
RU2194993C2 (ru) * 2000-12-28 2002-12-20 Научно-исследовательский институт вирусологии им.Д.И.Ивановского РАМН Способы ускоренной диагностики гепатита с, основанные на обнаружении гемагглютининов вируса гепатита с и антител к ним в рга и ртга в крови людей
CN102307589A (zh) * 2008-08-28 2012-01-04 沃泰克斯药物股份有限公司 Hcv的基因型分析
JP2013522302A (ja) * 2010-03-14 2013-06-13 グローブイミューン，インコーポレイテッド 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療

Also Published As

Publication number Publication date
KR20130036063A (ko) 2013-04-09
CN103052719A (zh) 2013-04-17
SG187106A1 (en) 2013-03-28
AU2011287642A1 (en) 2013-01-10
AU2011287642B2 (en) 2014-08-14
WO2012016995A1 (en) 2012-02-09
JP5756175B2 (ja) 2015-07-29
BR112013002531A2 (pt) 2016-05-31
MY183794A (en) 2021-03-16
KR101570914B1 (ko) 2015-11-20
CA2802272A1 (en) 2012-02-09
NZ604125A (en) 2014-08-29
RU2590691C2 (ru) 2016-07-10
EP2601313A1 (en) 2013-06-12
JP2013534138A (ja) 2013-09-02
RU2013109732A (ru) 2014-09-10
US20120196272A1 (en) 2012-08-02
CN103052719B (zh) 2016-04-13

Similar Documents

Publication Publication Date Title
MX2013001269A (es) Prediccion de cinetica viral de hcv en tratamiento libre de interferon.
MX349879B (es) Un polimorfismo de un solo nucleotido en el cromosoma 15 que predice las respuestas al tratamiento para el virus de la hepatitis c.
Han et al. Hand, foot, and mouth disease outbreak caused by coxsackievirus A6, China, 2013
MX2012011805A (es) Prediccion de respuesta viral precoz en el tratamiento contra hcv.
EP2542545A4 (en) INHIBITORS OF HEPATITIS C-VIRUS NS5B POLYMERASE
NZ595955A (en) Oligonucleotide comprising an inosine for treating dmd
WO2010093843A3 (en) Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
WO2006069064A3 (en) Conserved hbv and hcv sequences useful for gene silencing
MX2013011127A (es) Seleccion de tratamiento hcv.
Pratedrat et al. Single nucleotide polymorphisms in miR-149 (rs2292832) and miR-101-1 (rs7536540) are not associated with hepatocellular carcinoma in Thai patients with hepatitis B virus infection
EP1929042A4 (en) DETECTION OF MUTATIONS IN A GENE ASSOCIATED WITH RESISTANCE TO A VIRUS INFECTION, OAS2 OR OAS3
WO2010099169A3 (en) A novel in vitro hiv-1 latency model for screening reactivation agents of hiv-1
MX2012011804A (es) Polimorfismos de un solo nucleotido que predicen resultados de tratamiento de hcv.
GB201008123D0 (en) Novel compounds
MA35283B1 (fr) Produits de recombinaison destinés à inactiver le gène p0 et leur utilisation
GB2489180A (en) Method of predicting capecitabine toxicity
李巧艳 et al. Individuals Having Variant Genotypes of Cytochrome P450 2C19 Is at Increased Risk of Developing Primary Liver Cancer in Han Populations without Infection with Hepatitis Virus
Karkhane et al. Genetic Variations in Host Factors and their Critical Role on HCV Medication
Berkhout Hepatitis C virus therapy: blocking the little microRNA helper of the virus
Masaya et al. Genetic variation in IL-28B is associated with response to the therapy for chronic hepatitis C
UA127778U (uk) Спосіб прогнозування швидкості прогресування фіброзу печінки у хворих на hbv+hcv
NZ624258A (en) Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
Yu MicroRNA-146a rs2910164 polymorphism is associated with susceptibility to Type 2 Diabetes in the Chinese Han population
Suresh et al. Gene polymorphisms in CCR5, CCR2, CX3CR1, SDF-1 and RANTES in exposed but uninfected partners of HIV-1 infected individuals in North India
Liaudanski et al. GENOTYPE DISTRIBUTION IN PATIENTS WITH CHRONIC HEPATITIS C ANALYSIS USING MULTIFACTOR DIMENSIONALITY REDUCTION METHOD

Legal Events

Date Code Title Description
FA Abandonment or withdrawal